June 13, 2014

New approaches to treating cancer are creating big growth opportunities for the pharmaceutical industry, Moody's Investors Service stated in a report released Thursday titled "Cancer Breakthroughs Bring New Options for Patients and Revenue Streams to Big Pharma."

June 13, 2014

Teva Pharmaceutical Industries on Thursday announced that the U.S. Court of Appeals for the Federal Circuit upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb's entecavir compound claim of U.S. Patent No. 5,206,244 invalid.

June 12, 2014

Valeant Pharmaceuticals International announced that its subsidiary, Valeant Pharmaceuticals North America, received approval from the Food and Drug Administration for its new drug application for Jublia (efinaconazole 10% topical solution). The drug is the first topical triazole approved for the treatment of onychomycosis of the toenails, the company said.

June 12, 2014

The House Energy and Commerce Committee on Tuesday advanced bipartisan legislation sponsored by full committee vice chair Marsha Blackburn to address the nation’s growing prescription drug abuse epidemic.

June 10, 2014

Canada’s Federal court ruled recently that the country’s Patented Medicine Prices Review Board – a federal tribunal that regulates pricing on branded medicines – could not extend price control measures to cover generic drug companies.

June 9, 2014

Bayer last week named Dieter Weinand president of Bayer HealthCare Pharmaceuticals effective Aug. 1.

June 9, 2014

BioDelivery Sciences International on Monday announced that the Food and Drug Administration approved its new drug application for Bunavail (buprenorphine and naloxone) buccal film (CIII).

June 9, 2014

A recently approved drug might make infusions for hemophiliacs fewer and further between. The Food and Drug Administration approved Biogen Idec's Eloctate, which clinical trials have shown works to treat bleeding episodes and to increase the time between prophylactic blood infusions for those with hemophilia A.

June 2, 2014

Teva Pharmaceutical Industries on Monday announced a new organizational structure and executive positions. The changes, which will become effective July 1, are designed to improve global integration and effectiveness across the company, Teva said.

May 29, 2014

Depomed on Wednesday announced that the Food and Drug Administration has accepted for filing a new drug application from Mallinckrodt for MNK-155.

May 28, 2014

Actavis on Tuesday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration seeking approval to market saxagliptin hydrochloride tablets, 2.5 mg and 5 mg.

May 28, 2014

Sanofi and Eli Lilly and Co. on Wednesday announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil).

May 28, 2014

Taro Pharmaceutical Industries posted a net sales increase of 13.2% to $759.3 million for its fiscal year ended March 31.

May 23, 2014

The Food and Drug Administration took action this week against websites that sell potentially dangerous, unapproved prescription drugs to U.S. consumers.

May 22, 2014

Prasco Labs on Thursday announced it has entered into a distribution and supply agreement with Recordati Rare Diseases for the rights to distribute ibuprofen lysine injection, the authorized generic version of NeoProfen (ibuprofen lysine).

May 19, 2014

Pfizer on Sunday made a final offer valued at $118 billion for AstraZeneca. AstraZeneca, in turn, rejected the bid Monday morning.

May 16, 2014

Abbott announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence the company reported.

May 15, 2014

The stampede of big-selling branded medicines that hurtled off the patent cliff in 2011 and 2012 has slowed to a relative trickle.

May 15, 2014

The Generic Pharmaceutical Association lobbied for greater access to generics at this week’s meeting of the chief negotiators of the Trans-Pacific Partnership in Ho Chi Minh City, Vietnam, the association announced Wednesday.

May 15, 2014

Teva Pharmaceutical was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis, drug 10 days before the patent on the medication expires, according to a Bloomberg report published Thursday morning.

May 14, 2014

Actavis on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for a generic version of Mallinckrodt's Exalgo (hydromorphone hydrochloride extended-release tablets 8 mg, 12 mg and 16 mg).

May 13, 2014

Pfizer testified before British Parliament Tuesday regarding its proposed offer to acquire AstraZeneca, the New York Times reported.

May 13, 2014

Valeant Pharmaceuticals on Monday announced that certain of its subsidiaries have entered into settlement agreements with Actavis related to Actavis' generic versions of Tiazac XC.

May 9, 2014

Bayer agreed to acquire the consumer care business of U.S. pharmaceutical company Merck for a purchase price of $14.2 billion. The OTC acquisition will give Bayer the global No. 2 position in nonprescription products following recently announced consolidations in this growing healthcare industry segment, and will significantly enhance Bayer’s business across multiple therapeutic categories and geographies. Merck's consumer care business includes such leading brands as Claritin, Coppertone and Dr. Scholl’s. Pro forma sales of the combined businesses in 2013 amounted to $7.4 billion with Merck’s business contributing approximately $2.2 billion.

Upon completion of the acquisition, Bayer is expected to achieve global leadership positions in dermatology and gastrointestinals and advance to the No. 2 position in the cold, allergy, sinus and flu category. Bayer will remain No. 2 in nutritionals and No. 3 in analgesics. Overall, the proposed GlaxoSmithKline-Novartis combination represents the largest consumer health business with about 5.7% share, according to reports. The Bayer/Merck combination comes in second with around 4.5% share. McNeil Consumer rounds out the top three globally with a share just above 4%.